At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized Phase 2 Study of Oral Sapacitabine in Elderly Patients With Acute Myeloid Leukemia Previously Untreated or in First Relapse, or Previously Treated Myelodysplastic Syndromes
In Brief
A Phase 2 clinical trial evaluating Sapacitabine, Arm A, Sapacitabine, Arm B, and 7 other interventions for Acute Myeloid Leukemia. Completed, enrolled 105 participants across 15 sites.
Detailed Summary
The objective is to treat elderly AML and MDS patients with sapacitabine.
Study Details
Timeline
Interventions
200 mg b.i.d. x 7 days every 3-4 weeks
300 mg b.i.d. x 7 days every 3 - 4 weeks
400 mg b.i.d. x 3 days/week x 2 weeks every 3 - 4 weeks
200 mg b.i.d. x 7 consecutive days every 4 weeks
300 mg q.d. x 7 consecutive days every 4 weeks
300 mg b.i.d. x 3 consecutive days per week for 2 weeks every 4 weeks
200 mg b.i.d. x 7 consecutive days every 4 weeks
300 mg q.d. x 7 consecutive days every 4 weeks
100 mg q.d. x 5 consecutive days per week for 2 weeks every 4 weeks